KEVZARA (Sanofi-Aventis Australia Pty Ltd)
Product name
KEVZARA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
198 working days (255)
Active ingredients
sarilumab (rch)
Registration type
NCE/NBE
Indication
KEVZARA (solution for injection), in combination with non-biological disease-modifying anti-rheumatic drugs (DMARDs) or as monotherapy, is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have had an inadequate response or intolerance to one or more DMARDs.